Stryker Co. (NYSE:SYK) Stock Position Raised by Chicago Capital LLC

Chicago Capital LLC increased its position in Stryker Co. (NYSE:SYK) by 3.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 195,052 shares of the medical technology company’s stock after buying an additional 5,841 shares during the period. Stryker accounts for 1.9% of Chicago Capital LLC’s portfolio, making the stock its 19th largest holding. Chicago Capital LLC’s holdings in Stryker were worth $70,228,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Dunhill Financial LLC boosted its holdings in Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 37 shares in the last quarter. Darwin Wealth Management LLC acquired a new position in shares of Stryker during the 3rd quarter valued at about $36,000. Crews Bank & Trust acquired a new stake in Stryker in the 4th quarter worth approximately $39,000. HBW Advisory Services LLC bought a new stake in Stryker during the third quarter worth approximately $42,000. Finally, Hara Capital LLC bought a new position in shares of Stryker in the third quarter valued at approximately $42,000. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the transaction, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 5.50% of the stock is currently owned by company insiders.

Stryker Stock Performance

SYK stock opened at $390.90 on Monday. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The business’s fifty day moving average is $376.68 and its 200-day moving average is $363.02. The company has a market cap of $149.02 billion, a P/E ratio of 50.37, a price-to-earnings-growth ratio of 2.78 and a beta of 0.96.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the company posted $3.46 earnings per share. Equities research analysts forecast that Stryker Co. will post 13.5 EPS for the current year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Tuesday, December 31st were given a $0.84 dividend. The ex-dividend date of this dividend was Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. This is a boost from Stryker’s previous quarterly dividend of $0.80. Stryker’s dividend payout ratio is currently 43.30%.

Analyst Ratings Changes

A number of research analysts have weighed in on SYK shares. UBS Group upped their price target on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Piper Sandler reiterated an “overweight” rating and set a $420.00 price target (up from $380.00) on shares of Stryker in a report on Wednesday, October 30th. JPMorgan Chase & Co. raised their price objective on shares of Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Canaccord Genuity Group upped their target price on shares of Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Finally, Morgan Stanley upgraded shares of Stryker from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $370.00 to $445.00 in a report on Monday, December 2nd. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $419.37.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.